On April 23, 2026, the 10th Annual Everything Grows Conference was held in Hangzhou. During the conference, the Hangzhou Venture Capital Association, in collaboration with Chain Link and Bank of Hangzhou, officially released the "2026 Hangzhou Unicorn and Quasi-Unicorn Enterprise List." Zhejiang Doer Biologics Co., Ltd. has once again been named to the Hangzhou Quasi-Unicorn Enterprise List, marking the sixth time the company has received this honor.
According to the list, among Hangzhou's quasi-unicorn enterprises, the life health sector leads all ten major sectors with 118 companies. Doer Biologics' consecutive inclusion on the list from 2021 to 2026 not only represents continued recognition of the company's R&D strength and innovation-driven growth potential but also serves as a great encouragement for its commitment to independent innovation and persistent efforts.
In addition to honors such as being recognized as a High-tech Enterprise and an Intellectual Property Strong Enterprise, the company also hosts a National Postdoctoral Scientific Research Workstation and a Provincial R&D Center. Five innovative drug projects have successfully advanced into clinical studies. Looking ahead, Doer Biologics will continue to focus on the research of multi-domain, multispecific innovative biologics, striving to develop novel biologics with independent intellectual property rights that address unmet clinical needs. Staying true to the rigorous "DOER" scientific spirit, the company will uphold its corporate vision of contributing to human health through diligent and innovative work, advance the development of innovative biologics, and make steady, step-by-step contributions to improving human health.